Infections as Triggers for Thrombotic Thrombocytopenic Purpura (TTP)
Yes, infections can trigger Thrombotic Thrombocytopenic Purpura (TTP), with various viral and bacterial pathogens documented as potential precipitating factors for this life-threatening condition. 1, 2, 3
Mechanism and Evidence
Infections can trigger TTP through several mechanisms:
Immune System Activation: Infections may lead to immune stimulation that triggers autoantibody formation against ADAMTS13 (the enzyme that cleaves von Willebrand factor), resulting in acquired TTP 3
Endothelial Damage: Some infections directly damage vascular endothelium, which can precipitate the microvascular thrombosis characteristic of TTP 1
Relapse Trigger: In patients recovering from TTP, new infections can trigger early relapse, necessitating renewed treatment 2
Documented Infectious Triggers
Multiple infectious agents have been associated with TTP:
Viral infections:
Bacterial infections:
Other infections:
Clinical Implications
The relationship between infections and TTP has important clinical implications:
Diagnostic challenges: Systemic infections can mimic TTP's presenting features, making diagnosis difficult. In one registry, 7% of patients initially diagnosed with TTP were subsequently found to have systemic infections causing similar clinical manifestations 3
Treatment considerations:
- When infection is suspected as a trigger for TTP, appropriate antibiotic therapy should be instituted promptly 2
- In some cases, treating the underlying infection may lead to resolution of TTP 6
- Initial plasma exchange is still appropriate in critically ill patients with diagnostic features of TTP, even if infection is suspected 3
Monitoring for infections: Vigilance for new infections is essential in TTP patients undergoing treatment, as these can trigger relapses 2
Diagnostic Approach
When evaluating patients with suspected TTP:
- Consider infection as both a potential trigger and a differential diagnosis
- Perform appropriate infectious workup including blood cultures, urinalysis, chest imaging, and specific tests based on clinical presentation
- Remember that the presence of infection does not rule out TTP - they can coexist, with infection triggering TTP 3
- Be aware that some patients with infection-associated TTP may have severe ADAMTS13 deficiency with demonstrable inhibitors 3
Treatment Algorithm
For patients presenting with clinical features of TTP:
- Begin plasma exchange promptly if TTP is suspected clinically
- Simultaneously evaluate for potential infectious triggers
- Obtain ADAMTS13 activity and inhibitor levels before plasma exchange if possible
If infection is identified:
- Initiate appropriate antimicrobial therapy immediately
- Continue plasma exchange if TTP diagnosis remains likely
- Monitor response to both antimicrobial therapy and plasma exchange
For refractory cases:
Pitfalls and Caveats
- Misdiagnosis risk: The clinical features of severe systemic infections can closely mimic TTP, potentially leading to unnecessary plasma exchange 3
- Delayed diagnosis: Focusing exclusively on TTP may delay identification and treatment of underlying infections
- Treatment complications: Immunosuppressive treatments for TTP may worsen outcomes in patients with active infections
- Incomplete evaluation: Failure to perform comprehensive infectious workup in TTP patients may miss treatable triggers
Remember that the relationship between infections and TTP is bidirectional - infections can both trigger TTP and mimic its presentation. A thorough diagnostic evaluation and appropriate management of both conditions are essential for optimal patient outcomes.